Aclaris Therapeutics Stock Story
| ACRS Stock | USD 1.22 0.02 1.61% |
Slightly above 70% of Aclaris Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Aclaris Therapeutics stock suggests that many investors are alarmed at this time. Aclaris Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Aclaris Therapeutics. The current market sentiment, together with Aclaris Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Aclaris Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aclaris Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aclaris daily returns and investor perception about the current price of Aclaris Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Aclaris |
Requested story not found. it has been either deleted or moved. View all stories for Aclaris Therapeutics.
Aclaris Therapeutics Latest Timeline
Aclaris Therapeutics is listed for 1.22. About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.55. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 1.27. The entity had not issued any dividends in recent years.Check out Aclaris Therapeutics Hype Analysis, Aclaris Therapeutics Correlation and Aclaris Therapeutics Performance. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.